BioCardia, Inc. Operating Lease, Right-of-Use Asset, Amortization Expense
BioCardia, Inc. (BCDA) reported Operating Lease, Right-of-Use Asset, Amortization Expense of $242.00 thousand for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-12.
Financial Statements › Cash Flow › Operating Activities
us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense · last filed 2026-08-12
- BioCardia, Inc. operating lease, right-of-use asset, amortization expense for the quarter ending 2026-06-30 was $121.00K, a 2.54% increase year-over-year.
- BioCardia, Inc. operating lease, right-of-use asset, amortization expense for the quarter ending 2026-03-31 was $121.00K, a 0.00% change year-over-year.
- BioCardia, Inc. operating lease, right-of-use asset, amortization expense for the quarter ending 2025-12-31 was $182.00K, a 14.95% decline year-over-year.
- BioCardia, Inc. operating lease, right-of-use asset, amortization expense for the quarter ending 2025-09-30 was $60.00K, a 34.78% decline year-over-year.
- BioCardia, Inc. operating lease, right-of-use asset, amortization expense for fiscal 2025 was $481.00K, a 0.21% decline from fiscal 2024.
- BioCardia, Inc. operating lease, right-of-use asset, amortization expense for fiscal 2024 was $482.00K, a 47.40% increase from fiscal 2023.
- BioCardia, Inc. operating lease, right-of-use asset, amortization expense for fiscal 2023 was $327.00K, a 10.85% increase from fiscal 2022.
- BioCardia, Inc. operating lease, right-of-use asset, amortization expense for fiscal 2022 was $295.00K, a 49.14% decline from fiscal 2021.
| Period end | Operating Lease, Right-of-Use Asset, Amortization Expense 3 month | Operating Lease, Right-of-Use Asset, Amortization Expense 3 month as first filed | Operating Lease, Right-of-Use Asset, Amortization Expense 6 month | Operating Lease, Right-of-Use Asset, Amortization Expense 6 month as first filed | Operating Lease, Right-of-Use Asset, Amortization Expense 9 month | Operating Lease, Right-of-Use Asset, Amortization Expense 12 month | Operating Lease, Right-of-Use Asset, Amortization Expense 12 month as first filed |
|---|---|---|---|---|---|---|---|
| 2026-06-30 | $121.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-12 | $242.00K 10-Q · filed 2026-08-12 | $424.00K derived: sum of 3 quarters · filed 2026-08-12 | $484.00K derived: sum of 4 quarters · filed 2026-08-12 | |||
| 2026-03-31 | $121.00K 10-Q · filed 2026-05-15 | $303.00K derived: sum of 2 quarters · filed 2026-05-15 | $363.00K derived: sum of 3 quarters · filed 2026-05-15 | $481.00K derived: sum of 4 quarters · filed 2026-08-12 | |||
| 2025-12-31 | $182.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-24 | $242.00K derived: sum of 2 quarters · filed 2026-03-24 | $360.00K derived: sum of 3 quarters · filed 2026-08-12 | $481.00K 10-K · filed 2026-03-24 | |||
| 2025-09-30 | $60.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-12 | $178.00K derived: sum of 2 quarters · filed 2026-08-12 | $299.00K 10-Q · filed 2025-11-12 | $513.00K derived: sum of 4 quarters · filed 2026-08-12 | |||
| 2025-06-30 | $118.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-12 | $239.00K 10-Q · filed 2026-08-12 | $196.00K 10-Q · filed 2025-08-11 | $453.00K derived: sum of 3 quarters · filed 2026-08-12 | $545.00K derived: sum of 4 quarters · filed 2026-08-12 | ||
| 2025-03-31 | $121.00K 10-Q · filed 2026-05-15 | $97.00K 10-Q · filed 2025-05-14 | $335.00K derived: sum of 2 quarters · filed 2026-05-15 | $427.00K derived: sum of 3 quarters · filed 2026-05-15 | $516.00K derived: sum of 4 quarters · filed 2026-05-15 | ||
| 2024-12-31 | $214.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-24 | $306.00K derived: sum of 2 quarters · filed 2026-03-24 | $395.00K derived: sum of 3 quarters · filed 2026-03-24 | $482.00K 10-K · filed 2026-03-24 | $363.00K 10-K · filed 2025-03-26 | ||
| 2024-09-30 | $92.00K derived: 10-Q 9 month − 10-Q/A 6 month · filed 2025-11-12 | $181.00K derived: sum of 2 quarters · filed 2025-11-12 | $268.00K 10-Q · filed 2025-11-12 | $353.00K derived: sum of 4 quarters · filed 2025-11-12 | |||
| 2024-06-30 | $89.00K derived: 10-Q/A 6 month − 10-Q 3 month · filed 2025-10-29 | $176.00K 10-Q/A · filed 2025-10-29 | $261.00K derived: sum of 3 quarters · filed 2025-10-29 | $344.00K derived: sum of 4 quarters · filed 2025-10-29 | |||
| 2024-03-31 | $87.00K 10-Q · filed 2025-05-14 | $172.00K derived: sum of 2 quarters · filed 2025-05-14 | $255.00K derived: sum of 3 quarters · filed 2025-05-14 | $335.00K derived: sum of 4 quarters · filed 2025-05-14 | |||
| 2023-12-31 | $85.00K derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-26 | $168.00K derived: sum of 2 quarters · filed 2025-03-26 | $248.00K derived: sum of 3 quarters · filed 2025-03-26 | $327.00K 10-K · filed 2025-03-26 | |||
| 2023-09-30 | $83.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-13 | $163.00K derived: sum of 2 quarters · filed 2024-11-13 | $242.00K 10-Q · filed 2024-11-13 | $318.00K derived: sum of 4 quarters · filed 2024-11-13 | |||
| 2023-06-30 | $80.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-13 | $159.00K 10-Q · filed 2024-08-13 | $235.00K derived: sum of 3 quarters · filed 2024-08-13 | $310.00K derived: sum of 4 quarters · filed 2024-08-13 | |||
| 2023-03-31 | $79.00K 10-Q · filed 2024-05-14 | $155.00K derived: sum of 2 quarters · filed 2024-05-14 | $230.00K derived: sum of 3 quarters · filed 2024-05-14 | $303.00K derived: sum of 4 quarters · filed 2024-05-14 | |||
| 2022-12-31 | $76.00K derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-27 | $151.00K derived: sum of 2 quarters · filed 2024-03-27 | $224.00K derived: sum of 3 quarters · filed 2024-03-27 | $295.00K 10-K · filed 2024-03-27 | |||
| 2022-09-30 | $75.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-08 | $148.00K derived: sum of 2 quarters · filed 2023-11-08 | $219.00K 10-Q · filed 2023-11-08 | $381.00K derived: sum of 4 quarters · filed 2023-11-08 | |||
| 2022-06-30 | $73.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-09 | $144.00K 10-Q · filed 2023-08-09 | $306.00K derived: sum of 3 quarters · filed 2023-08-09 | $450.00K derived: sum of 4 quarters · filed 2023-08-09 | |||
| 2022-03-31 | $71.00K 10-Q · filed 2023-05-10 | $233.00K derived: sum of 2 quarters · filed 2023-05-10 | $377.00K derived: sum of 3 quarters · filed 2023-05-10 | $516.00K derived: sum of 4 quarters · filed 2023-05-10 | |||
| 2021-12-31 | $162.00K derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-29 | $306.00K derived: sum of 2 quarters · filed 2023-03-29 | $445.00K derived: sum of 3 quarters · filed 2023-03-29 | $580.00K 10-K · filed 2023-03-29 | |||
| 2021-09-30 | $144.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-09 | $283.00K derived: sum of 2 quarters · filed 2022-11-09 | $418.00K 10-Q · filed 2022-11-09 | ||||
| 2021-06-30 | $139.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-10 | $274.00K 10-Q · filed 2022-08-10 | |||||
| 2021-03-31 | $135.00K 10-Q · filed 2022-05-11 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| DYADIC INTERNATIONAL INC (DYAI) | United States | $0.016B | |
| Passage BIO, Inc. (PASG) | United States | $0.015B | -0.43 |
| Pluri Inc. (PLUR) | $0.014B | ||
| INTENSITY THERAPEUTICS, INC. (INTS) | United States | $0.013B | -1.08 |
| BRAINSTORM CELL THERAPEUTICS INC. (BCLI) | United States | $0.013B | -1.05 |
| Jasper Therapeutics, Inc. (JSPR) | United States | $0.020B | -0.37 |
| Estrella Immunopharma, Inc. (ESLA) | United States | $0.020B | |
| IN8BIO, INC. (INAB) | United States | $0.012B | -0.76 |
| Senti Biosciences Holdings, Inc. (SNTI) | United States | $0.011B | -0.70 |
| TScan Therapeutics, Inc. (TCRX) | United States | $0.008B | -1.23 |